Past Events

NICHD is seeking research co-development partners and/or licensees for a newly developed wearable, wireless device and protocol. The technology continuously monitors the placental oxygenation levels, multiple physiological signals and movement activities of a fetus and mother. Attend a free webinar on October 9th to hear from Amir Gandjbakhche, Ph.D., the inventor, and learn about the technology.

An annual event for potential industry partners and stakeholders highlighting cancer technologies and how to work with the NCI and the Frederick National Laboratory.

This webinar was originally scheduled for January 31, and rescheduled for May 22; it will now be rescheduled for fall 2024.
Attendees will learn about a potential, novel treatment for Retinitis Pigmentosa (RP). Over 100,000 in the U.S. and 1.5 million people worldwide suffer from RP, which leads to progressive photoreceptor cell degeneration and ultimately vision loss. A new therapeutic technology from the National Eye Institute has the potential to be a treatment option for RP patients and may also protect retinal cells from damage associated with glaucoma and age-related macular degeneration (AMD). Attend the webinar to assess the technology for partnership and licensing opportunities.

Webinar attendees will learn about a new family of Proteolysis Targeting Chimeras (PROTACS) that selectively target Proviral Integration for the Moloney murine leukemia virus (PIM) kinases. PIM kinases play a role in cancer development and mediating resistance to radio and chemotherapy, and are overexpressed in multiple cancers. Several small molecule PIM kinase inhibitors have had minimal effect in suppressing cancer phenotypes due to the PIM kinase inhibitors promoting intrinsic resistance. By contrast, these PIM-targeted PROTACs suppress PIM kinase activity and avoid intrinsic resistance.

In this free webinar hosted by TTC, attendees will learn about a new adjuvanted subunit mucosal Covid-19 vaccine that incorporates a unique nanoparticle formulation. In vivo study results demonstrated that it can protect against respiratory SARS-CoV-2 exposure and may enhance the protective effect of systemic vaccines. This makes it a good candidate for a SARS-CoV-2 vaccine. Attend the webinar to hear from the NCI inventor and learn more about the technology which is available for collaboration and licensing.

In this free, NIH webinar hosted by TTC, attendees will learn about a first-of-its-kind male contraceptive hormonal gel, Nestorone/Testosterone (NES/T), co-developed by the NICHD and Population Council through the Contraceptive Clinical Trials Network (CCTN). This topical daily self-applied transdermal gel is designed to provide full sperm suppression within 8-12 weeks and be reversible after 12-16 weeks of ending application. This presentation will showcase NES/T gel as an innovative user-controlled option for male contraception.

Learn about a technology opportunity webinar presented by the inventor of a new medical device, Dr. Stephen Adler of the NCI. The NCI is seeking partners to further develop the technology entitled "Automated Benchtop Acoustophoresis Device to Radio-Label & Isolate Cells for Immunotherapy Treatment"

Attend a free webinar to assess co-developing an NCI technology, "Anti-EGFR Antibodies for the Treatment of Human Cancers." The presentation will follow a logical sequence of how anti-EGFR antibodies are generated and modified to make them cytotoxic for tumor cells.

Register for the 2023 Technology Showcase on September 6th.

The NCI Technology Transfer Center will host a technology opportunity webinar on Wednesday, August 23 from 11:00 a.m. - 12:00 p.m. ET that will highlight a new therapeutic target in pancreatic cancer. Dr, Mitchell Ho, deputy chief, NCI Laboratory of Molecular Biology, is the featured presenter.